British Journal of General Practice

BackgroundEarlier identification and registration of people in the last year of life improves care quality and outcomes in general practice. However, there is little evidence on patients who subsequently no longer require end-of-life registration, nor on the safety or outcomes of de-registration following clinical review. AimTo determine the prevalence, safety, and prognostic validity of GP-led removal from the end-of-life register (EOL_R) using a systematic digital review process. Design and SettingObservational cohort study in eight practices in Wolverhampton, UK, using a whole-population integrated primary and secondary care dataset. MethodAll adults on the EOL_R were systematically reviewed using a digital end-of-life pathway (PRADA) incorporating robotic process analysis of recognised end-of-life care markers. GPs recorded a binary decision to retain or remove patients from the register. Mortality outcomes were compared with those retained on the EOL_R, a tightly propensity-matched cohort not on the register, and the residual general population over 15 months. ResultsOf 422 registered patients, 33 (7.8%) were removed following GP assessment. One-year survival in the removed group was statistically indistinguishable from the propensity-matched control cohort, and survival was significantly higher versus those retained on the EOL_R (60.4%, p<0.001). Removal demonstrated a negative predictive value for mortality of 90.9%. ConclusionGP-led removal from the end-of-life register can be undertaken safely and identifies a distinct group with substantially better prognosis. Digital systems that support systematic review, documentation, and follow-up should be incorporated into routine practice and reflected in national guidance and the Quality and Outcomes Framework. Statement boxesO_ST_ABSWhat is knownC_ST_ABSEarlier identification and registration of people in the last year of life improves care coordination and outcomes. However, little is known about patients who subsequently no longer require end-of-life registration, or whether removal following clinical review is associated with adverse outcomes. What this study addsIn a whole-population primary care cohort, General Practitioners removed 33 patients (7.8% of those registered) from the end-of-life register following structured clinical review. One-year survival in this group was equivalent to a tightly matched cohort not on the register, and survival was substantially higher than among patients retained on the register. A simple robotic based review process can prompt systematic reassessment, capture GP clinical judgement, and enable prospective monitoring following removal. ImplicationsEnd-of-life registration should be treated as a dynamic process requiring ongoing clinical review. Digital systems can support safe removal from registers by documenting decisions and embedding follow-up for patients whose prognosis remains uncertain. Evidence-based guidance and governance processes for a review process are needed to ensure people are not retained on registers unnecessarily. How this fits inEnd-of-life registers are intended to support proactive care for people in their last year of life, yet there is little evidence about patients who later stabilise and may no longer require registration. In eight UK practices, a systematic GP review supported by a digital end-of-life pathway identified a small but clinically important group suitable for removal, without adverse mortality outcomes. Beyond improving register accuracy, structured review creates opportunities for meaningful dialogue with patients, shared reassessment of care goals, and appropriate de-escalation of end-of-life labelling. Embedding routine, structured review with documented decisions and follow-up may also reduce unnecessary clinical workload and strengthen governance in primary care. Novelty StatementSystematic GP review of end-of-life registers, as stipulated in GMC guidance, is rarely evaluated. We propose a digitally driven, systematic and dynamic clinical-governance-led approach to register review.

Background In 2024, one-third of GP appointments in England were conducted by telephone. What happens during these consultations is largely unknown. Aim To test the feasibility of collecting recorded GP telephone consultations with linked data and consent for future research use. Design and setting Retrospective observational study in seven practices in South West England. Method Adults who had a telephone consultation at practices that routinely record calls were invited to consent to retrieval of call audio, a 4-month electronic health record (EHR) extract and a post-consultation patient questionnaire. Practice-level consent rates were analysed using regression models. Results Of 28 clinicians recruited, 19 GPs had consultations with patients whose recordings were retrievable, usable, and consented for future research. Of 2,053 invitations, 123 patients consented (6.0%). Consent was lower in more deprived practices (IMD 1-2 vs 9-10: OR=0.22, 95CI=0.09-0.54). Of 101 recordings retrieved, 96 were usable and 91 had consent for future research. 86/91 were linked to EHRs and 89/91 to post-consultation patient questionnaires. Mean consultation duration was 7 minutes 13 seconds; audible typing was heard in 69% (63/91). 161 problems were discussed (mean 1.77 per consultation). Most patients were happy their consultation was by telephone (96/117, 82%), although the majority reported usually preferring face-to-face appointments (68/115, 59%). Conclusion It is feasible to assemble a reusable archive of GP telephone consultations with linked data. However, recruitment was low using retrospective remote consent. Future work should test alternative recruitment approaches, particularly to improve patient engagement at practices serving deprived populations.

Objective: The shortage of general practitioners (GPs) in Australia has intensified interest in team-based care for hypertension, involving pharmacists and nurses. This study explored primary care provider experiences, barriers, and facilitators related to implementing team-based care in Australia. Design: Qualitative study using semi-structured interviews with primary care providers. Methods: We conducted 51 interviews with GPs (n=24), nurses (n=12), and pharmacists (n=15), purposively selected from diverse primary care settings. Analysis combined deductive coding, informed by the Theoretical Domains Framework and Consolidated Framework for Implementation Research, with inductive thematic analysis to identify emergent themes. Results: Interviews demonstrated a predominantly GP-centred care model, with nurse and pharmacist involvement largely confined to supporting roles, including blood pressure measurement, prescription refills, patient follow-up and counselling. Their contributions were constrained by barriers at both practice (e.g., limited GP support, fragmented communication across providers) and health system levels (e.g., limited financial incentives and restricted reimbursement pathways). Despite their critical role in care planning, nurses described being hamstrung by workload and limited direct funding for hypertension-related services. Pharmacists reported unreimbursed blood pressure checks and restricted funding for medication reviews that constrained the sustainability of their hypertension services. Role ambiguity and the absence of standardised protocols on task sharing further limited collaboration, with nurses and pharmacists describing concerns about overstepping professional boundaries. Attitudes towards team-based care ranged from active disregard (outright rejection) to conditional acceptance and occasional active uptake (strong endorsement). Conclusion: Despite clear willingness among nurses and pharmacists to alleviate GP burden, team-based care is rarely implemented in routine practice. Addressing system-level barriers (funding models that incentivise team-based care and standardised treatment protocols that clarify shared workflows), alongside provider-level barriers (stronger awareness and training that normalises task sharing), is critical to support genuine team-based hypertension care in Australia.

BackgroundPrimary care practitioners are well-positioned to support people of reproductive age in preparing for pregnancy and parenthood. Such "preconception care" is ideally delivered opportunistically during routine consultations, although limited time presents a barrier. AimTo achieve consensus on priority topics for opportunistic preconception care in general practice. Design and settingA three-step consensus study involving UK-based primary care practitioners and people of reproductive age. MethodThe consensus process involved: 1) identifying potential topics through literature and guideline reviews, workshops with people of reproductive age (n=15), and interviews with primary care practitioners who work in general practice (n=14); 2) prioritising topics using a Delphi survey (n=85 participants completing round one, n=63 completing all three rounds); and 3) agreeing on priority topics during an online consensus workshop (n=21 participants). Participants were recruited through a Public Advisory Group, charities, and professional organisations. ResultsReviews and workshops/interviews with people of reproductive age and practitioners identified 37 potential topics. The Delphi survey and consensus workshop identified 16 priority topics. These were combined into four overarching topic areas for discussion during relevant consultations: O_LIPatient knowledge of preconception health and pregnancy C_LIO_LIIdeas, concerns and expectations (e.g. pregnancy intention, prior pregnancy experiences) C_LIO_LIHealth conditions (e.g. medication use, mental/physical health, immunisation) C_LIO_LIHealth behaviours (e.g. folic acid supplement use, smoking, alcohol consumption). C_LI ConclusionThe agreed priority topic areas offer a structured foundation for delivering patient-centred, opportunistic preconception care in primary care. The findings support future co-development of practical tools and resources to enable routine implementation. How this fits inPreconception care improves pregnancy outcomes, but in UK general practice it is inconsistently delivered, partly due to limited time and guidance that offers little prioritisation for opportunistic consultations. This study identifies four overarching topic areas for preconception care, based on consensus among people of reproductive age and primary care practitioners. The resulting priority list offers clinicians a practical, flexible way to initiate patient-centred preconception care discussions within routine consultations.

BackgroundInteractive dashboards can support safe prescribing but effectiveness depends on user engagement. The research team developed a prescribing safety dashboard, deployed in 27 Irish general practices. Trend graphs tracked prescribing changes (2019-2025) by practices across key metrics. This study explored how GPs engaged with the dashboard and their perceptions of using routine data for prescribing feedback. MethodsPrescribers from participating practices were invited to online interviews (May-August 2025). A think-aloud exercise involved participants verbalising their thoughts while navigating the dashboards, followed by a semi-structured interview exploring views on safe prescribing, feedback and data access. Interviews were recorded, auto-transcribed and manually reviewed for accuracy. Think-aloud data were analysed deductively using a sense-making framework, interviews analysed inductively, and findings triangulated to refine themes. ResultsNine general practitioners (GPs) from eight practices participated. Themes were organised into four categories: (1) Perceptions of open data, (2) Perceptions of feedback, (3) Dashboard engagement, and (4) High-quality prescribing. Most were in favour of open data and transparency but some feared misuse. GPs valued feedback but reported workload as a barrier. Engagement with the dashboard was mainly interpretative, focused on data meaning in the context of their practice. GPs showed a strong emotional dimension to engagement and also described intended actions in response to what they saw. Finally, high-quality prescribing was mainly viewed as avoiding harm. ConclusionsGPs valued and engaged with dashboard feedback but workload competed with time for reflection and action-highlighting the need for practical, streamlined tools and nudges to support engagement. Key messagesO_LIAudit and feedback, such as that delivered through interactive dashboards has a small but significant effect on professional behaviours such as prescribing, but user engagement influences effectiveness. C_LIO_LIIrish GPs engaged with a prescribing safety and quality dashboard in a reflective and contextual way and garnered rich insights on their prescribing. C_LIO_LIGPs valued feedback and showed a strong emotional attachment to their performance, but felt workload competed with time for reflection and action. C_LIO_LIWith advances in data infrastructure, it is possible to provide interactive prescribing feedback in real time. However, the way feedback is designed and delivered plays a crucial role in supporting engagement. Dashboards and related behavioural interventions should be co-designed with prescribers to maximise engagement. C_LI

Multimorbidity, the co-existence of two or more long-term conditions, is up to three times more prevalent among people with cancer than in the general population and is associated with poorer survival, particularly for cancers with a more favourable prognosis such as colorectal cancer. In Scotland, multimorbidity is the norm among older adults, emerges earlier in socioeconomically deprived populations, and may contribute to comparatively low cancer survival rates. Despite this, the influence of multimorbidity on the colorectal cancer pathway remains poorly understood. We conducted a Scottish data-linkage study of adults diagnosed with colorectal cancer between 2010 and 2014, linking the Scottish Cancer Registry to national prescribing, hospital admissions, death registration, and bowel screening datasets. Prescribing data were used to derive overall and system-specific comorbidity measures as a proxy for multimorbidity and active disease burden. Associations with stage at diagnosis, treatment, survival, and screening uptake were examined using logistic regression and Cox proportional hazards models adjusted for demographic and clinical covariates. Among 19,043 patients, 87% had at least one prescribing-based comorbidity, most commonly cardiovascular, nervous system, and gastrointestinal conditions. Overall comorbidity burden was not associated with stage at diagnosis, although laxative-related prescribing was associated with later-stage disease. Increasing comorbidity burden reduced the likelihood of receiving any treatment and surgery, while associations varied across system-specific comorbidities. Higher comorbidity burden was also associated with increased all-cause and colorectal cancer-specific mortality, particularly among patients with respiratory, nervous system, and haematological/nutritional conditions. Screening uptake was not associated with overall comorbidity burden but did differ by system-specific comorbidity. Prescribing-based multimorbidity was highly prevalent and strongly associated with treatment patterns and mortality among patients with colorectal cancer. System-specific multimorbidity measures provided greater discrimination than overall morbidity counts, highlighting the importance of considering distinct multimorbidity profiles when assessing cancer pathways and designing targeted interventions for optimising treatment and survival. Keywords (primary health care, general practice, multimorbidity, comorbidity, colorectal cancer, early diagnosis, cancer treatment, survival)

Social prescribing has assumed increasing dominance in policy and practice internationally, including in the UK, where it has an increasing role in addressing social needs such as isolation, and social determinants of ill-health. Although General Practitioners are perceived as key referral sources, social workers in one locality were found to play a significant role in referral. This suggests that the social work role in this context has been under-recognised and under-explored. This study sought to explore social workers perceptions and experiences of social prescribing through an online survey conducted from January - June 2022. All UK social workers were eligible to participate, regardless of whether they had made referrals. Responses (105) were collected from all UK nations. Data was analysed using inductive thematic analysis. Four key themes were generated: contended and contested boundaries; complementary spaces; delineated spaces of simplicity and complexity; social work under threat. Participants recognised that social prescribing could provide valuable client support and could be a useful resource for social workers. However, they also expressed concerns about overlapping professional boundaries and the potential for social prescribing to encroach on social work, perceiving it as most appropriate for the delivery of support to those with low-level needs.

Background: High blood pressure (BP) is an often treatable cause of cardiovascular disease. We developed an intervention, featuring a cardiovascular expert team and a toolbox, to support healthcare professionals (HCPs) in hypertension management and enhance patient self-management. Aim: This study evaluates the adoption and feasibility of this intervention. Design and Setting: A mixed-methods study in general practices in the Netherlands. Methods: HCPs could consult a cardiovascular expert team and use a self-management toolbox for their patients as preferred. We interviewed HCPs guided by the Consolidated Framework of Implementation Research (CFIR), and HCPs completed the Determinants of Implementation Behaviour Questionnaire (DIBQ). Using CFIR-ERIC matching tool, we matched implementation strategies to identified barriers. Adults with elevated BP, who were prescribed at least two blood pressure lowering medications were eligible to participate. Patient and disease characteristics were extracted from the electronical medical record. Results: Of 591 eligible patients at thirteen general practices, 176 participated. The cardiovascular expert team was well-received, with 33 unique consultations, although nurse practitioners (NPs) might need the expertise of the expert team more frequently than general practitioners (GP) (adoption). The toolbox was perceived as challenging to use (feasibility). We subsequently identified three key strategies to improve implementation. Mean systolic and diastolic BP were 158/87 mmHg at baseline and 148/85 mmHg after 12 months, although this change cannot be conclusively linked to the intervention. Conclusions: Structured implementation strategies may be helpful in hypertension management. The cardiovascular expert team was considered valuable, but might be better targeted to NPs rather than GPs.

BackgroundAlthough virtual consultations are increasingly used in healthcare, mode affects attendance patterns remains limited, particularly across demographic groups. Within NHS secondary care, telephone consultations have been the most widely adopted form of telephone care; however, few studies have examined non-attendance (commonly termed Did Not Attend [DNA]) patterns specifically for telephone consultations and fewer still have explored how patient characteristics influence attendance differently across consultation modes. Understanding these patterns is essential for equitable service planning. ObjectiveTo compare non-attendance rates between telephone and in-person secondary care consultations among adults with type 2 diabetes (T2D), and to identify patient characteristics associated with non-attendance under each mode. MethodsData from 853,693 secondary care consultations (January 2020-August 2024) for 45,618 patients with T2D in Northwest London were analysed. Telephone consultations in this dataset consisted exclusively of telephone consultations; we therefore refer to them as telephone consultations throughout. Patient-level consultations were aggregated into patient-mode strata for regression modelling. Zero-inflated Negative Binomial regression assessed factors associated with missed consultation rates by mode (in-person or telephone). Propensity-score balance diagnostics (inverse probability of treatment weighting) were conducted to assess measured confounding by mode assignment. Specialty-stratified non-attendance rates were examined across 34 major specialties. ResultsIn-person consultations had higher unadjusted non-attendance rates than telephone consultations (9.1% vs 7.2%, p<0.001). This pattern was consistent for both first consultations (9.3% vs 6.2%, p<0.001) and follow-up consultations (9.0% vs 7.50%, p<0.001). For in-person consultations, higher non-attendance was associated with younger age (18-39: 12.2%, 40-59: 11.1% vs 60-79: 9.9%, p<0.001), Black or Black British ethnicity (18.9% vs White: 7.6%, p<0.001), and greater deprivation (most deprived IMD1: 10.3% vs least deprived IMD5: 7.0%, p<0.001). For telephone consultations, higher non-attendance was associated with male gender (7.3% vs female: 7.0%, p<0.01), younger age (18-39: 11.3%, 40-59: 9.5% vs 60-79: 6.1%, 80+: 5.6%, p<0.001), and greater socioeconomic deprivation (most deprived: 8.3% vs least deprived: 4.7%, p<0.001). Interaction analyses revealed that demographic disparities were amplified for telephone relative to in-person consultations. Specialty-stratified analysis showed that in-person non-attendance exceeded telephone non-attendance in the majority of high-volume specialties. ConclusionsIn-person consultations had higher non-attendance rates than telephone consultations. Various demographic factors influenced non-attendance rates, with younger age and greater socioeconomic deprivation consistently associated with non-attendance for both in-person and telephone consultations. These findings suggest that a personalised, equity-informed approach to consultation mode selection is needed. Findings apply to telephone consultations and may not generalise to video-based modalities.

IntroductionAccess to specialist care in the Netherlands requires a general practitioner (GP) referral, yet referrals to secondary care keep rising. Triage has been proposed to manage this demand and may be relevant for internal medicine, which addresses diverse and increasingly complex conditions. This study aimed to identify the internal medicine healthcare needs which were redirected to the GP after triage and to explore the factors driving GP referral behaviour. MethodsThis multi-method study combined quantitative referral data with qualitative insights from GP focus groups. Data were extracted from a hospital in an urban region, including adults with non-acute complaints referred for outpatient consultation to internal medicine between August 2019 and July 2021. Referrals were triaged for appropriateness and redirected where possible. Focus groups explored GPs perspectives on referral practices. ResultsOf 5,826 referrals triaged, 998 (17%) were redirected to the GP with advice and guidance. Endocrinology accounted for 35% of redirected cases, followed by nephrology (8.6%). Focus groups revealed underlying drivers of referral behaviour, identifying four themes: medical factors; GP-related factors, including professional uncertainty and autonomy; patient-related factors; and external factors, such as contextual and regulatory influences. ConclusionThis study demonstrates that triage is a feasible strategy for managing referral volumes, particularly within domains such as endocrinology where many medical problems can be managed in primary care. However, referrals are shaped by more than clinical need, reflecting uncertainty, emotional considerations, patient expectations and systemic factors. Strengthened collaboration between primary and secondary care, alongside pre-referral consultation strategies, is essential to ensure appropriate, high-quality patient care.

BackgroundThe COVID-19 pandemic significantly accelerated the adoption of telemedicine, but it also exposed gaps in effective remote clinical assessment, particularly for medically vulnerable patients in rural areas. The ORCHARD intervention aimed to address this by providing patients with a Medical Self-Assessment Box to enable self-reporting of vital signs during remote consultations. MethodsA single-centre randomised mixed-methods feasibility trial recruited medically vulnerable patients from a rural general practice in Northeast Scotland. Participants in intervention group received a home medical equipment box for use during telemedicine consultations over six months. Patients and GPs were interviewed and transcripts were analysed using Framework Analysis. ResultsTwelve (15%) of 82 eligible invited patients enrolled. Six each were allocated to intervention and control group. 50%(n=3)patients in intervention group used equipment in 45%(5 of 11)teleconsultations and rated it helpful in all 5 uses (100%). The intervention group had 18% fewer primary care contacts than controls. All remote consultations were by telephone. Framework Analysis of patient interviews identified facilitators such as ease of use, improved triage access, reassurance, and barriers related to GP non-engagement and written instructions. GP interviews identified clinical value in patient-generated readings, alongside concerns regarding workload and patient over-monitoring. ConclusionsHalf of intervention participants used the medical-equipment box during remote consultations, all finding it useful, though frequency of use varied among particpants.A randomised controlled trial to evaluate the effectiveness of the Medical Self-Assessment Box for optimising remote consulting in medically vulnerable rural patients is feasible.Prior to a definitive trial refinements are recommended to patient labelling, GP engagement, and training materials.

Objectives We aimed to describe the characteristics of children and young people referred to social prescribing across the UK and understand what social prescribing looks like for these young people. Additionally, we aimed to explore whether access to and experiences of social prescribing vary with age and have changed from 2017 to 2025. Overall, we aimed to identify whether social prescribing reduces or exacerbates health inequalities among children and young people, and whether this has changed over time. Design Analysis of social prescribing electronic health records Setting Social prescribing hubs and services across the UK that use Access Elemental (a cloud-based social prescribing platform) Participants 52,585 individuals referred to social prescribing in 2017-2025 aged 4-25 years (mean=20.04, SD=4.71), of whom 57% were female, 39% male, <2% were in other gender groups, and 3% did not disclose their gender Primary and secondary outcome measures We summarised the characteristics of young people and described the care pathway received. We then used regression models to test whether these factors differed by age and over time. Results Most individuals were aged 18 and over, 91% lived in urban areas and 58% lived in the top three most deprived deciles of the UK. Most were referred by GPs or other allied health workers (79%) and mental health was the leading reason for referral (44%). The typical pathway included 4.64 social prescribing contacts (SD=7.70) totalling 66 minutes (SD=108), with 34% receiving an onward referral to community support. The average age of those referred to social prescribing increased over time. Conclusions Our findings indicate that social prescribing currently has limited reach for those under 18 and this disparity may be increasing. It was promising that children and young people referred to social prescribing were more likely to live in deprived areas. However, given current findings, more work is needed to increase the reach of social prescribing for children and young people across the UK.

BackgroundRoutinely collected prescribing and medicine-related data in Scotland are comprehensive and of high quality. However, they are generated across multiple healthcare settings and stored in complex source systems that are not optimised for longitudinal or outcomes-focused research. To maximise the research value of these data, there is a need for curated, analysis-ready resources that provide consistent representations of medicines exposure and enable linkage to clinical outcomes. The Medicines in Acute and Chronic care Scotland (MACCS) provides standardised, curated medicines data to support longitudinal analyses of medicine-related exposure across NHS healthcare systems. MethodsMACCS resource is a national individual-level medicines dataset for adults (18 years of age and older), derived from routinely collected prescribing and medicine-related data held by Public Health Scotland (PHS). It integrates data from the Hospital Electronic Prescribing and Medicines Administration (HEPMA), Prescribing Information System (PIS), and Homecare Medicines (HCM) datasets, which are linked at the individual level to eleven other national clinical records; including Scottish Morbidity Records (SMR00/01/02/04/06), laboratory data and mortality records; using the unique NHS Scotland person identifier. Data are curated, harmonised and pre-linked within the National Safe Haven and accessed by approved researchers through secure Trusted Research Environments. ResultsMACCS contains individual-level information on adults receiving NHS Scotland care, including patient demographics (such as age, sex and geographical indicators) and detailed records of medicines prescribing in community pharmacies as well as those administered in hospitals and through homecare services. Medicines-related data captures exposure dates and, where available, details on formulation, strength and dose. In addition, MACCS includes cancer registry data, renal registry data, laboratory test results, microbiology surveillance and mortality records. The earliest dates of data availability vary by source dataset. ConclusionMACCS provides a sustainable, longitudinal medicines research resource that simplifies access to complex national prescribing data and enables robust linkage to health outcomes. By supporting population-scale analyses across care settings, MACCS enhances the capacity for high-quality research to inform clinical practice, health policy, and medicines optimisation in Scotland. Key FeaturesO_LIThe Medicines in Acute and Chronic Care in Scotland (MACCS) data resource was established in 2025 to integrate medicine-related data with other electronic data from Scottish healthcare systems, creating a national, linked, routinely updated data resource at population level. C_LIO_LIMACCS provides pre-linked data from multiple routinely collected national datasets within NHS Scotland including, but not limited to, prescribing records, hospital episodes, laboratory results, and death records, within a single secure environment. C_LIO_LIMACCS includes patient demographics, data on medicines prescribing and administration/supply, key biochemistry and haematology test results (e.g., kidney and liver function tests), data on hospital admissions and surgical procedures, and date and cause of death. C_LIO_LIThe data resource provides longitudinal follow-up of the adult population ([&ge;]18 years of age) receiving medicines through NHS Scotland since 2010, covering approximately 4.6 million individuals, and supports pharmacoepidemiological studies, drug utilisation research, pharmacovigilance projects, as well as health services research. C_LIO_LIApproved researchers can apply through a streamlined process to access the linked MACCS data resource through established NHS Scotland governance processes, with data accessed within a Trusted Research Environment. C_LI

ObjectiveThe aim of this study was to develop and validate an automated, scalable framework to harmonise fragmented UK primary care prescription records into a research-ready dataset by mapping four diverse medical ontologies to a unified, historically comprehensive reference standard. Materials and MethodsWe used raw prescription records for consented participants in the UK Biobank, in which participants are uniquely characterized by multiple data modalities. Primary care data were preprocessed by selecting one drug code if multiple were recorded, cleaning codes to match reference presentations, expanding code granularity based on drug descriptions, and updating outdated codes to a single reference version. Harmonisation entailed mapping British National Formulary (BNF) and Read2 codes to dm+d, the universal NHS standard vocabulary for uniquely identifying and prescribing medicines. Harmonised dm+d records were then homogenised to a single concept granularity, the Virtual Medicinal Product (VMP). We validated our methods by creating medication profiles mapping contemporary drug prescribing patterns in 312 physical and mental health conditions. ResultsWe preprocessed 57,659,844 records (100%) from 221,868 participants (100%). Of those, 48,950 records were dropped due to lack of drug code. 7,357,572 records (13%) used multiple ontologies. Most (76%) records were encoded in BNF and most had the code granularity expanded via the drug description (N=28,034,282; 49%). 41,244,315 records (72%) were harmonised to dm+d and 99.98% of these were converted to VMP as a homogeneous dataset. Across 312 diseases, we identified 23,352 disease-drug associations with 237 medications (represented as BNF subparagraphs) that survived statistical correction of which most resembled drug - indication pairs. ConclusionOur methodology converts highly fragmented and raw prescription records with inconsistent data quality into a streamlined, enriched dataset at a single reference, version, and granularity of information. Harmonised prescription records can be easily utilised by researchers to perform large-scale analyses in research.

Abstract Background Between 2021 and 2022, primary care obesity management was entering the early diffusion phase of newer anti obesity pharmacotherapy, as GLP1 based treatments began reshaping expectations. However, it was unclear whether primary care clinicians and practice environments were prepared to deliver comprehensive obesity care. (1,2) Methods In 2021 to 2022, we surveyed 276 clinicians from three cohorts: an opt-in national physician panel (Cohort A), clinicians from an integrated health system (Cohort B), and clinicians from a rural accountable care organization (Cohort C). The survey, informed by formative patient and physician focus groups conducted in 2021, assessed current and desired competence, attitudes, confidence, perceived forces for change, and barriers to obesity care. Analyses were descriptive (means and standard deviations). Results Across cohorts, desired competence exceeded current competence. The largest gaps involved recommending behavioral interventions, developing comprehensive care plans, and providing ongoing obesity management support. Attitudes toward obesity care were generally favorable, while confidence that current practices reflected best practice was only moderate. Professional and personal forces for change were moderate, patient driven motivators were moderate to high, whereas social (peer/organizational) reinforcement was weak. Reported barriers extended beyond knowledge deficits to include patient engagement, competing demands, cost, and practical constraints. Conclusions At the threshold of the GLP1 era, primary care clinicians were motivated to improve obesity care but lacked consistent support to deliver comprehensive management. The relative absence of peer and organizational reinforcement suggests that readiness for change reflected not only individual knowledge and attitudes, but also the degree of peer and organizational reinforcement that supports comprehensive obesity care in routine practice.

BackgroundCardiovascular disease (CVD) risk is managed in primary care using lipid-lowering therapies (LLTs) and antihypertensives (AHTs) for primary (no prior CVD) or secondary (with prior CVD) prevention, but patients may discontinue treatment. Little synthesised real-world data for LLT/AHT discontinuation exists. MethodsWe systematically reviewed English language reports of observational studies from PubMed, EMBASE, Web of Science, and CINAHL published from 2010-2025 describing discontinuation/restarting prevalence for first-to-third line LLTs/AHTs used for CVD prevention in primary care (PROSPERO: CRD420250599340). Data were extracted on discontinuation/restarting prevalences and associations between discontinuation and sociodemographic factors. FindingsOf 5,756 records, 31 (16 LLT; 15 AHT) reports were included representing 9,146,252 patients. Risk of bias was generally low except for two papers with substantial risk of bias from unmeasured confounding. LLT median (IQR) discontinuation and restarting prevalences were 43% (38%; 54%) and 43% (22%; 64%), respectively. AHT discontinuation and restarting prevalences were 41% (30%; 49%) and 28%, respectively. Discontinuation/restarting prevalence depended on discontinuation definition and indication. Patients aged around 65 years old were less likely to discontinue than younger or older patients, for both LLTs and AHTs. Women discontinued LLTs more often irrespective of indication; men discontinued AHTs more often for primary prevention. Income-based socioeconomic position (SEP) measures were associated with discontinuation, but composite SEP measures were not. Minority ethnic groups were more likely to discontinue LLTs and AHTs. InterpretationThis systematic review of real-world data identified discontinuation inequities in first-to-third line LLTs and AHTs based on age, sex, and ethnicity. Awareness of these patterns and additional research into patient-level drivers of drug discontinuation could improve health equity by addressing LLT/AHT discontinuation in the highest-risk patients. FundingThis work was funded by the NIHR UCLH BRC. No funders had any role in data collection, analysis, manuscript preparation, or the decision to publish. Research in contextWe searched PubMed for reviews, systematic reviews, and meta-analyses examining associations between age, sex, socioeconomic position, ethnicity (search string: "sociodemograph*" OR "age" OR "sex" OR "socioeconomic status" OR "socioeconomic position" OR "ethnic*" OR "race" OR "racial" OR "Asian*" OR "India*" OR "Pakistan*" OR "Bangladesh*" OR "Black" OR "African" OR "Afro*") and discontinuation (search string: persist* or discontinu* or stop*) of antihypertensives/lipid-lowering drugs (search string: "anti$hypertensive" OR "blood*pressure lowering" OR "ACE inhibitor" OR "angiotensin receptor blocker" OR "calcium channel blocker" OR "thiazide-like diuretic" OR "thiazide diuretic" OR "lipid*lowering" OR "lipid*reducing" OR "statin" OR "HMG-CoA reductase inhibitors" OR "proprotein convertase subtilisin/kexin type 9" OR "PCSK9 inhibitor"). We did not restrict reports by date or language. Of 711 results, one relevant article was found. Two more relevant articles were found in the searches performed for this systematic review. One 2017 systematic review of twenty-two real-world studies found that for nineteen studies with a dichotomous discontinuation outcome, 16% to 93% of patients discontinued statins across follow-up time of 0 days (cross-sectional studies) to median 4.1 years follow-up. The authors did not report on the proportion of patients discontinuing by sociodemographic group. A 2018 systematic review and meta-analysis of RCTs and real-world data found that for patients aged [&ge;]65, lower income was associated with discontinuation across seven studies (odds ratio [95% confidence interval] 1{middle dot}20 [1{middle dot}06 to 1{middle dot}36]), though the degree of heterogeneity in the studies used for meta-analysis was high (I2 = 0.89). Female gender (1{middle dot}03 [0{middle dot}98 to 1{middle dot}09]) was not associated with statin discontinuation, and there was a trend towards an association between Black/non-White race and discontinuation (1{middle dot}57 [0{middle dot}92-2.68]). A 2024 systematic review of 52 RCTs and real-world studies found that the prevalence of statin discontinuation ranged from 0.8% to 70.5%, and was higher for primary prevention, and that male sex and non-White ethnicity were associated with statin discontinuation. Our search found no prior systematic reviews or meta-analyses describing differences in discontinuation of AHTs by age, sex, SEP or ethnicity. Added value of this studyThis study is the first systematic review of sociodemographic factors influencing antihypertensive discontinuation in primary care, and complements the findings described above with new evidence on statin discontinuation in real-world settings. With respect to statins and/or ezetimibe, we found that younger (below 60) and older (above 75) patients were more likely to discontinue statins, for both primary and secondary prevention. Female sex was associated with a small but consistent increase in statin discontinuation across our included studies. Individual income appeared to associate with statin discontinuation, but not composite SEP measures such as the Indices of Multiple Deprivation. For antihypertensives, we found that younger and older patients were more likely to discontinue for both primary and secondary prevention, with discontinuation at its lowest around 70 years. Male sex was associated with a small but consistent increase in discontinuation in primary prevention but was associated with marginally reduced discontinuation in a larger study of patients using AHTs for mixed prevention. Lower individual income appeared to positively associate with antihypertensive discontinuation, but composite SEP measures did not. In all studies reporting ethnic differences in discontinuation, non-majority ethnic groups were consistently more prone to discontinuation. Implications of all the available evidenceNon-persistence rates for lipid-lowering medications and antihypertensives are considerable and constitute a possible avenue to reduce CVD. In the first comprehensive evidence synthesis across socio-demographic groups, we show discontinuation rates in real-world settings differ across groups, which may contribute to existing health inequities. For statins, it is unclear how sex associates with discontinuation, given the inconsistency of results across different systematic reviews and meta-analyses. Low income and minority ethnic group membership are associated with statin discontinuation. Our findings suggest that commonly used AHTs are discontinued more often in men than in women, in the youngest and oldest patients, and in minority ethnic groups. Lower individual income may associate with statin discontinuation, but belonging to a lower SEP group such those derived from the Indices of Multiple Deprivation was not associated with statin discontinuation. Future research efforts should address the intersectionality in these patterns, to ascertain whether sociodemographic disadvantages combine to drive higher discontinuation rates in specific patient subgroups. Data on discontinuation by the type of LLT/AHT used (e.g. angiotensin-converting enzyme inhibitor versus for AHTs) should also be collated. Causes for antihypertensive/lipid-lowering medication discontinuation should be investigated using qualitative methods to ascertain reasons for discontinuation in patient groups directly, utilising underrepresented patient populations where possible. Data from such qualitative studies may inform future interventions to reduce discontinuation in the most at-risk patient groups. Clinicians should heighten efforts to maintain or reinitiate therapy in those prone to lipid-lowering therapy and antihypertensive discontinuation, assuming no clinical contraindications.

Background Advice and Guidance (A&G) enables primary care clinicians to seek specialist input, supporting decision making and avoiding unnecessary referrals. The use of A&G has significantly expanded, accelerated by COVID19 and contractual changes. While A&G is intended to streamline elective care, concerns persist regarding workload shift, variable responsiveness, and system usability. Despite growing policy emphasis, little is known about why clinicians choose to use A&G. Aim Explore the current use of A&G within primary care, focusing on decision making processes which underpin PCCs' decision to use A&G. Design and Setting Qualitative study set in English Primary Care Method Twenty semi structured video interviews were conducted with primary care clinicians purposively sampled for maximum variation. Topic guides were developed with PPIE input and refined iteratively. Data were analysed using reflexive thematic analysis within an interpretive description framework, with themes developed collaboratively and refined through discussion with researchers and PPIE contributors. Ethical approval was obtained (REC 333799). Results Four overarching themes encapsulate clinicians' decisions to use A&G: clinical presentation (acuity and complexity), navigating healthcare pathways, previous experiences of A&G, and using A&G to validate clinical decision making. Barriers included delayed responses and uncertainty about inequitable workload distribution. These factors shape how effectively A&G could be integrated into routine practice. Conclusion Primary care clinicians use A&G to support patient care and aid decision-making, but its effectiveness depends on timely, clinically helpful responses. Ensuring responses remain appropriate to primary care remit and capacity will be essential if A&G becomes the main route into elective care.

ObjectivesAn update to the NICE Type 2 diabetes (T2DM) guideline in February 2022 recommended an SGLT2 inhibitor be offered to people with cardiovascular disease (CVD) or heart failure (HF) as comorbidities and considered for people at high CVD risk. We report uptake of this guideline in England 18 months after its publication. DesignObservational cohort study. SettingGeneral practices contributing to the Clinical Practice Research Data Link, linked to hospital admission records. Participants587,826 people aged over 18 years with T2DM on 1st September 2023, stratified according to their CVD category (CVD only; HF only; CVD and HF; high CVD risk score; low CVD risk score) and chronic kidney disease (CKD) status, and further by age, gender, ethnicity, deprivation, and T2DM diagnosis duration. Main outcome measuresPercentage of patients with a current SGLT2 inhibitor prescription; odds ratios for association between patient characteristics and a current prescription. ResultsIn people with T2DM, the percentage with a current SGLT2 inhibitor prescription was 19.5% for people with CVD, 29.4% for people with HF, 30.5% for people with both CVD and HF, and 19.9% and 20.2% respectively for people at high and low CVD risk. In age-stratified analyses, uptake ordered from lowest to highest was as follows: low CVD risk score, high CVD risk score, CVD only, HF only, CVD and HF. In models adjusted for clinical and patient characteristics uptake was lower in people aged >60, women, Black people, and people living in areas of higher deprivation. ConclusionsWhilst prescribing of SGLT2 inhibitors continues to rise in England, an opportunity remains to increase uptake and to reduce inequalities in people with T2DM in 2026. We report inequalities by ethnicity and deprivation, and lower uptake for people with CVD without HF than people with HF, despite an equal guideline recommendation for these two groups. Additional evidence is needed on the effectiveness of SGLT2 inhibitors in frailer populations. What is already known on this topic?O_LIIn 2020 approximately 10% of people with type 2 diabetes (T2DM) and cardiovascular disease (CVD) and 14% of people with T2DM but without CVD in England had a current SGLT2 inhibitor prescription. C_LIO_LIIn February 2022 NICE recommended that an SGLT2 inhibitor should be offered to people with T2DM with heart failure or CVD, and considered for people with T2DM at high risk of CVD; network meta-analyses have found 10% to 40% lower odds of cardiovascular mortality with treatment in these groups. C_LIO_LIUptake of NICE guidelines in general practice has historically been variable, although higher when accompanied by pay-for-performance schemes such as the Quality and Outcomes Framework. C_LI What this study addsO_LIBy September 2023 the percentage of people with T2DM with a current SGLT2 inhibitor prescription had reached 19.5% in those with CVD as a comorbidity, 30.5% in those with heart failure, and 19.9% in those at high risk of CVD. C_LIO_LIWomen, people of Black ethnicity, and people living in areas of high deprivation had lower odds of a current prescription in analyses adjusted for age, gender, cardiovascular comorbidity, and renal function. C_LI How might these results change the focus of research or clinical practice?O_LIThe results highlight the need for ongoing surveillance of uptake of NICE-recommended treatments for T2DM, and consideration of actions to address barriers to uptake. This is particularly important in the context of broader eligibility for SGLT2 inhibitor treatment in type 2 diabetes in England from 2026. C_LIO_LIThese results support the development of initiatives and quality improvement programmes to improve evidence-based prescribing and address inequalities between clinical and demographic subgroups. C_LI

To characterise the potential learning effects from a GenAI-based clinical decision support tool (CDST), we examined clinician behaviour within a cluster-randomised trial. The tool, AI Consult, parsed clinician notes written (in real-time) to document patient encounters and would raise green, yellow, or red flags to indicate no, potential, or critical risks of harm (respectively) in decisions the clinician made. Over several months, clinicians with access to the AI Consult tool produced fewer red (Intervention: 14% reduction, p = 0.032 vs. Control: 6% increase, p = 0.383) and yellow flags (Intervention: 6.8% reduction, p = 0.005 vs. Control: 3% increase, p = 0.231), whereas those without access to the tool showed no such effect. If this type of learning effect is a consistent emergent property across CDSTs, there might be an opportunity to reimagine their purpose: from addressing gaps in care quality to instead being a health system-strengthening investment.

Introduction: Hypertension is the world's leading cause of death, and depression its leading cause of disability. Control rates for these noncommunicable diseases (NCDs) are low in low and middle-income countries (LMICs). Many LMICs have programs to screen and treat underserved communities for infectious diseases, but evidence to adapt them to treat NCDs is limited. We developed and tested a non-communicable disease program through Ghana's Community-Based Health Planning and Services (CHPS) primary care initiative. Methods: We trained 8 CHPS nurses to diagnose and treat hypertension and depression through door-to-door screening and pharmacotherapy. Physician assistants provided telehealth supervision. We combined this treatment with volunteer counseling to boost medication adherence, improve mood, and change health behaviors. We called the 90-day intervention the CHPS Opportunity for Mentally and Behaviorally Integrated NCD Engagement (COMBINE). Results: We recruited 60 adults from 580 screened: 37 with hypertension (mean blood pressure (BP) of 149/91 mm Hg) and 23 with depression (mean physician health questionnaire (PHQ-9) score of 13.3). After 90 days, 57/60 (95%) completed the intervention: 32/37 (86%) achieved blood pressure control (mean BP 122/75 mm Hg), and 19 of 20 (95%) achieved depression control (mean PHQ-9 score 2.0). After 12 months, 51/60 were retained: 33/37 with hypertension (89%) and 18/23 with depression (78%), with a mean BP of 121/75 and PHQ-9 score of 1.4 respectively. All 51 (100%) achieved disease control at 12 months. 5 persons left by migration and 4 by escalation to higher-level care. Conclusions: The COMBINE model achieved high levels of diagnosis, care retention, and disease control, with minimal adverse events, in a remote setting with limited usual NCD care. This model suggests a novel means to improve the care cascade for these and other noncommunicable diseases through existing non-physician care models in LMICs, warranting further controlled testing at scale.